Novo Nordisk, Valo and Drug Discovery

Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and artificial intelligence (AI).
Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact
The deal extends an agreement to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and AI.
Novo Nordisk Expands Drug Discovery Collaboration With Valo Health For Cardiometabolic Diseases
Wednesday announced an expansion of its collaboration with Valo Health to discover and develop novel treatments for obesity, type-2 diabetes, and cardiovascular disease, committing to a near-term payment of $190 million.
Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss drug.
Novo Nordisk expands drug collaboration with Valo Health
Denmark's Novo Nordisk on Wednesday announced an expansion of its collaboration with Valo Health to discover and develop novel treatments for obesity, type-2 diabetes, and cardiovascular disease. It has committed to a near-term payment of $190 million and the collaboration expects milestone payments of approximately $4.
Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
Here's what Big Pharma could buy in 2025, from obesity drugs to precision cancer treatments, according to a top M&A banker
Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...
Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?
A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...
WGBH10h
How do GLP-1 drugs work for weight loss?
Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame ...
The Hill9d
RFK Jr. vs. Oz sets up clash on weight loss drug coverage
Currently, only 13 states cover GLP-1 drugs for obesity under Medicaid. But a new proposal announced by the Biden ...
UNC physician: Weight loss drugs save lives, but they’re too hard to obtain | Opinion
Obesity is more than a cosmetic concern. It’s a chronic disease that can be treated with drugs like semaglutide (Wegovy) and ...
Medpage Today on MSN10dOpinion
CMS Moved to Expand Obesity Drug Coverage. Private Insurers Need to Step Up.
This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...
Opinion
Comment: High bar set for success of new wave of obesity drugs
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...
FDA issues draft guidance on developing weight loss drugs
The U.S. FDA has released a new draft guidance for drugmakers to aid them in developing new treatments for obesity. The new ...